{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:23:54Z","timestamp":1787009034637,"version":"build-2736575974"},"reference-count":70,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,5,1]]},"DOI":"10.1093\/jac\/dkm033","type":"journal-article","created":{"date-parts":[[2007,3,29]],"date-time":"2007-03-29T20:49:32Z","timestamp":1175201372000},"page":"977-989","source":"Crossref","is-referenced-by-count":19,"title":["Cost-effectiveness of empirical prescribing of antimicrobials in community-acquired pneumonia in three countries in the presence of resistance"],"prefix":"10.1093","volume":"59","author":[{"given":"Monique","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibilia","family":"Quilici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"File","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Garau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar","family":"Kureishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Kubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2007,3,29]]},"reference":[{"key":"key\n\t\t\t\t20171010153928_DKM033C1","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1086\/313954","article-title":"Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America","volume":"31","author":"Bartlett","year":"2000","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171010153928_DKM033C2","article-title":"Streptococcus pneumoniae and community-acquired pneumonia: a cause for concern","volume":"117","author":"File","year":"2004","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t20171010153928_DKM033C3","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1086\/500140","article-title":"The impact of penicillin resistance on short-term mortality in hospitalized adults with pneumococcal pneumonia: a systematic review and meta-analysis","volume":"42","author":"Tleyjeh","year":"2006","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171010153928_DKM033C4","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/S1201-9712(03)90065-8","article-title":"Why do we need to eradicate pathogens in respiratory tract infections?","volume":"7","author":"Garau","year":"2003","journal-title":"Int J Infect Dis"},{"key":"key\n\t\t\t\t20171010153928_DKM033C5","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.3201\/eid0909.020810","article-title":"Fluoroquinolone and macrolide treatment failure in pneumococcal pneumonia and selection of multidrug-resistant isolates","volume":"9","author":"Perez-Trallero","year":"2003","journal-title":"Emerg Infect Dis"},{"key":"key\n\t\t\t\t20171010153928_DKM033C6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3201\/eid0901.020277","article-title":"Maintaining fluoroquinolone class efficacy: review of influencing factors","volume":"9","author":"Scheld","year":"2003","journal-title":"Emerg Infect Dis"},{"key":"key\n\t\t\t\t20171010153928_DKM033C7","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1164\/ajrccm.163.7.at1010","article-title":"Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention","volume":"163","author":"Niederman","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t20171010153928_DKM033C8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/jac\/49.1.31","article-title":"Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence","volume":"49","author":"Ball","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171010153928_DKM033C9","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1046\/j.1469-0691.2003.00573.x","article-title":"In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000\u20132001","volume":"9","author":"Jones","year":"2003","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20171010153928_DKM033C10","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/jac\/dkg321","article-title":"The Alexander Project 1998\u20132000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents","volume":"52","author":"Jacobs","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171010153928_DKM033C11","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1378\/chest.125.6.2140","article-title":"Treatment costs of community-acquired pneumonia in an employed population","volume":"125","author":"Colice","year":"2004","journal-title":"Chest"},{"key":"key\n\t\t\t\t20171010153928_DKM033C12","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2165\/00019053-200422110-00003","article-title":"Economic aspects of pneumococcal pneumonia: a review of the literature","volume":"22","author":"De Graeve","year":"2004","journal-title":"Pharmacoeconomics"},{"key":"key\n\t\t\t\t20171010153928_DKM033C13","first-page":"1413","article-title":"Community acquired pneumonia: higher mortality than traffic accidents","volume":"53","author":"Leophonte","year":"2003","journal-title":"Rev Prat"},{"key":"key\n\t\t\t\t20171010153928_DKM033C14","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00108-004-1156-0","article-title":"Competence network \u201ccommunity acquired pneumonia\u201d (CAPNETZ). A first interim report","volume":"45","author":"Welte","year":"2004","journal-title":"Internist (Berl.)"},{"key":"key\n\t\t\t\t20171010153928_DKM033C15","article-title":"Hospitalisation costs for community-acquired pneumonia (CAP) in France (F), Germany (D), Japan (J) and USA","volume":"24","author":"Neiss","year":"2004","journal-title":"Eur Resp J"},{"key":"key\n\t\t\t\t20171010153928_DKM033C16","first-page":"509","article-title":"Assessing the cost implications of microbiological sensitivity to antibiotic treatment in lower respiratory tract infections (LRTI)","volume-title":"Abstracts of the Fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 2000","author":"Boles"},{"key":"key\n\t\t\t\t20171010153928_DKM033C17","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3201\/eid0702.010228","article-title":"Economic impact of antimicrobial resistance","volume":"7","author":"McGowan","year":"2001","journal-title":"Emerg Infect Dis"},{"key":"key\n\t\t\t\t20171010153928_DKM033C18","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1056\/NEJM199701233360402","article-title":"A prediction rule to identify low-risk patients with community-acquired pneumonia","volume":"336","author":"Fine","year":"1997","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171010153928_DKM033C19","unstructured":"Agence Francaise de S\u00e9curit\u00e9 Sanitaire des Produits de Sant\u00e9\n          Antibiotherapie par voie generale en practique courante: infections respiratoires basses de l'adulte\n          2002\n          6 February 2006\n          \n            http:\/\/www.agmed.sante.gouv.fr"},{"key":"key\n\t\t\t\t20171010153928_DKM033C20","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1183\/09031936.98.11040986","article-title":"Guidelines for management of adult community-acquired lower respiratory tract infections. European Respiratory Society","volume":"11","author":"ERS Task Force Report","year":"1998","journal-title":"Eur Respir J"},{"key":"key\n\t\t\t\t20171010153928_DKM033C21","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00063-006-1040-x","article-title":"What is new in the treatment of community-acquired pneumonia?","volume":"101","author":"Welte","year":"2006","journal-title":"Med Klin (Munich)"},{"key":"key\n\t\t\t\t20171010153928_DKM033C22","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s15010-001-1020-2","article-title":"Hospitalization decision for ambulatory patients with community-acquired pneumonia: a prospective study with general practitioners in France","volume":"29","author":"Laurichesse","year":"2001","journal-title":"Infection"},{"key":"key\n\t\t\t\t20171010153928_DKM033C23","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4081\/monaldi.2005.654","article-title":"GP management of community-acquired pneumonia in Italy: the ISOCAP study","volume":"63","author":"Sanguinetti","year":"2005","journal-title":"Monaldi Arch Chest Dis"},{"key":"key\n\t\t\t\t20171010153928_DKM033C24","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1183\/09031936.03.00045202","article-title":"Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia","volume":"21","author":"Torres","year":"2003","journal-title":"Eur Respir J"},{"key":"key\n\t\t\t\t20171010153928_DKM033C25","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1378\/chest.119.1.185","article-title":"Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults","volume":"119","author":"Petitpretz","year":"2001","journal-title":"Chest"},{"key":"key\n\t\t\t\t20171010153928_DKM033C26","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1053\/rmed.2001.1113","article-title":"The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia","volume":"95","author":"Hoeffken","year":"2001","journal-title":"Respir Med"},{"key":"key\n\t\t\t\t20171010153928_DKM033C27","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1345\/aph.1C066","article-title":"Clinical experience with moxifloxacin in patients with respiratory tract infections","volume":"38","author":"Faich","year":"2004","journal-title":"Ann Pharmacother"},{"key":"key\n\t\t\t\t20171010153928_DKM033C28","first-page":"748","article-title":"Efficacy and safety of moxifloxacin vs clarithromycin for community-acquired pneumonia","volume":"16","author":"Fogarty","year":"1999","journal-title":"Infect Med"},{"key":"key\n\t\t\t\t20171010153928_DKM033C29","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1007\/s100960050201","article-title":"Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Azithromycin Study Group","volume":"17","author":"O'Doherty","year":"1998","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20171010153928_DKM033C30","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0149-2918(04)90005-7","article-title":"Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults","volume":"26","author":"Mathers","year":"2004","journal-title":"Clin Ther"},{"key":"key\n\t\t\t\t20171010153928_DKM033C31","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/jac\/dkh356","article-title":"Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia","volume":"54","author":"Tellier","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171010153928_DKM033C32","first-page":"1499","article-title":"Oral empiric treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. The Scandinavian Sparfloxacin Study Group","volume":"110","author":"Ortqvist","year":"1996","journal-title":"Chest"},{"key":"key\n\t\t\t\t20171010153928_DKM033C33","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.rmed.2004.04.007","article-title":"Gemifloxacin once daily for 7 days compared to amoxicillin\/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin","volume":"98","author":"Leophonte","year":"2004","journal-title":"Respir Med"},{"key":"key\n\t\t\t\t20171010153928_DKM033C34","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/jac\/37.3.555","article-title":"Comparison of oral cefuroxime axetil and oral amoxycillin\/clavulanate in the treatment of community-acquired pneumonia","volume":"37","author":"Higuera","year":"1996","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171010153928_DKM033C35","first-page":"225","article-title":"Enterolithiasis","volume":"28","author":"Gupta","year":"1982","journal-title":"J Postgrad Med"},{"key":"key\n\t\t\t\t20171010153928_DKM033C36","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1128\/AAC.46.3.783-786.2002","article-title":"Comparison of in vitro activities of ABT-773 and telithromycin against macrolide-susceptible and -resistant streptococci and staphylococci","volume":"46","author":"Shortridge","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171010153928_DKM033C37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijantimicag.2004.03.003","article-title":"Clarithromycin in 2003: sustained efficacy and safety in an era of rising antibiotic resistance","volume":"24","author":"Anzueto","year":"2004","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20171010153928_DKM033C38","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jac\/dkf806","article-title":"Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999\u20132000 study","volume":"50","author":"Farrell","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171010153928_DKM033C39","first-page":"117","article-title":"The comparative in vitro activity of moxifloxacin against respiratory tract pathogens isolated during 2003 from Libra-targeted surveillance","volume":"10","author":"Morrisey","year":"2004","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20171010153928_DKM033C40","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/jac\/dkh313","article-title":"Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001-2002, as part of the PROTEKT US study","volume":"54","author":"Brown","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171010153928_DKM033C41","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/jac\/dkf808","article-title":"Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and compatative in vitro activity of the ketolide, telithromycin","volume":"50","author":"Felmingham","year":"2002","journal-title":"J Antimicrob Chemother."},{"key":"key\n\t\t\t\t20171010153928_DKM033C42","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0163-4453(03)00123-3","article-title":"Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01","volume":"48","author":"Doern","year":"2004","journal-title":"J Infect"},{"key":"key\n\t\t\t\t20171010153928_DKM033C43","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S1201-9712(03)90066-X","article-title":"How can we predict bacterial eradication?","volume":"7","author":"Jacobs","year":"2003","journal-title":"Int J Infect Dis"},{"key":"key\n\t\t\t\t20171010153928_DKM033C44","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S1201-9712(03)90067-1","article-title":"Achieving bacterial eradication using pharmacokinetic\/pharmacodynamic principles","volume":"7","author":"Dagan","year":"2003","journal-title":"Int J Infect Dis"},{"key":"key\n\t\t\t\t20171010153928_DKM033C45"},{"key":"key\n\t\t\t\t20171010153928_DKM033C46","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1345\/aph.1E217","article-title":"Increased bacterial resistance: PROTEKT US\u2014an update","volume":"38","author":"Rybak","year":"2004","journal-title":"Ann Pharmacother"},{"key":"key\n\t\t\t\t20171010153928_DKM033C47","volume-title":"Dictionnaire Vidal","year":"2005","edition":"81st edition"},{"key":"key\n\t\t\t\t20171010153928_DKM033C48","volume-title":"Red Book. Pharmacy's Fundamental Reference","year":"2005"},{"key":"key\n\t\t\t\t20171010153928_DKM033C49","volume-title":"Rote Liste","year":"2005"},{"key":"key\n\t\t\t\t20171010153928_DKM033C50","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1378\/chest.120.1.185","article-title":"Clinical evaluation of the management of community-acquired pneumonia by general practitioners in France","volume":"120","author":"Fantin","year":"2001","journal-title":"Chest"},{"key":"key\n\t\t\t\t20171010153928_DKM033C51","volume-title":"Union des Caisses Nationales de Securite Sociale","year":"2004"},{"key":"key\n\t\t\t\t20171010153928_DKM033C52","unstructured":"PMSI (Programme de M\u00e9dication des Syst\u00e8mes d'Information)\n          Agence Technique de l'information sur l'Hospitalisation, Paris\n          4 February 2006\n          \n            http:\/\/www.atih.sante.fr"},{"key":"key\n\t\t\t\t20171010153928_DKM033C53","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0149-2918(98)80144-6","article-title":"The cost of treating community-acquired pneumonia","volume":"20","author":"Niederman","year":"1998","journal-title":"Clin Ther"},{"key":"key\n\t\t\t\t20171010153928_DKM033C54","volume-title":"CPT Current Procedural Terminology 2005","author":"American Medical Association","year":"2004"},{"key":"key\n\t\t\t\t20171010153928_DKM033C55","unstructured":"Blue Cross Insurance\n          Emergency Department Cost USA. 2005\n          2 November 2005\n          \n            http:\/\/www.bcbs.com\/mcrg\/index.html"},{"key":"key\n\t\t\t\t20171010153928_DKM033C56","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3109\/13814780109094331","article-title":"GP home visiting in 18 European countries","volume":"7","author":"Boerma","year":"2001","journal-title":"Eur J Gen Pract"},{"key":"key\n\t\t\t\t20171010153928_DKM033C57","unstructured":"Kassen\u00e4rztliche Bundesvereinigung\n          Einheitlicher Bewertungsma\u00dfstab f\u00fcr \u00e4rztliche Leistungen (EBM)\n          2 February 2006\n          \n            http:\/\/www.kbv.de\/"},{"key":"key\n\t\t\t\t20171010153928_DKM033C58","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1183\/09031936.98.11010073","article-title":"Empirical therapy for nonhospitalized patients with community-acquired pneumonia. Study Group of General Practitioners","volume":"11","author":"Laurichesse","year":"1998","journal-title":"Eur Respir J"},{"key":"key\n\t\t\t\t20171010153928_DKM033C59","unstructured":"Oregon State University\n          Student Health Services: Most Common Fees\n          6 February 2006\n          \n            http:\/\/studenthealth.oregonstate.edu\/costs\/index.php"},{"key":"key\n\t\t\t\t20171010153928_DKM033C60","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.3201\/eid0812.010533","article-title":"Outpatient antibiotic use and prevalence of antibiotic-resistant pneumococci in France and Germany: a sociocultural perspective","volume":"8","author":"Harbarth","year":"2002","journal-title":"Emerg Infect Dis"},{"key":"key\n\t\t\t\t20171010153928_DKM033C61","unstructured":"Deutsche Krankenhausgesellschaft, Spitzenverb\u00e4nde der Krankenkassen & Verband der privaten Krankenversicherung\n          Website der Selbstverwaltung f\u00fcr German refined \u2014 diagnosis Related Groups\n          11 December 2005\n          \n            http:\/\/www.dkgev.de"},{"key":"key\n\t\t\t\t20171010153928_DKM033C62","unstructured":"ENL Medical\n          Costs White Blood Cell Count, WBC\n          6 December 2004\n          \n            http:\/\/www.enlmedical.com"},{"key":"key\n\t\t\t\t20171010153928_DKM033C63","first-page":"182","article-title":"Advances in cost-effectiveness analysis of health interventions","author":"Garber","year":"2000","journal-title":"Handbook of Health Economics"},{"key":"key\n\t\t\t\t20171010153928_DKM033C64","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000080692","article-title":"Antimicrobial resistance of Streptococcus pneumoniae isolates of outpatients in Germany, 1999\u20132000","volume":"50","author":"Reinert","year":"2004","journal-title":"Chemotherapy"},{"key":"key\n\t\t\t\t20171010153928_DKM033C65","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1093\/jac\/dkg220","article-title":"Impact of antimicrobial resistance on health outcomes in the out-patient treatment of adult community-acquired pneumonia: a probability model","volume":"51","author":"Singer","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171010153928_DKM033C66","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/jac\/dkf512","article-title":"Implications of antimicrobial resistance in the empirical treatment of community-acquired respiratory tract infections: the case of macrolides","volume":"50","author":"Lonks","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171010153928_DKM033C67","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0732-8893(03)00087-7","article-title":"Comparison of Streptococcus pneumoniae and Haemophilus influenzae susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: five-year results for the SENTRY Antimicrobial Surveillance Program","volume":"46","author":"Gordon","year":"2003","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20171010153928_DKM033C68","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1086\/430906","article-title":"Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes?","volume":"41","author":"Doern","year":"2005","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171010153928_DKM033C69","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000077889","article-title":"Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Germany and activity of the ketolide telithromycin: results from the PROTEKT surveillance study (1999-2000)","volume":"50","author":"Reinert","year":"2004","journal-title":"Chemotherapy"},{"key":"key\n\t\t\t\t20171010153928_DKM033C70","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1128\/AAC.49.7.2903-2913.2005","article-title":"Antimicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003","volume":"49","author":"Reinert","year":"2005","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/59\/5\/977\/2164329\/dkm033.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,10]],"date-time":"2017-10-10T18:31:18Z","timestamp":1507660278000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jac\/article\/59\/5\/977\/728216\/Costeffectiveness-of-empirical-prescribing-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3,29]]},"references-count":70,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2007,3,29]]},"published-print":{"date-parts":[[2007,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkm033","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published-other":{"date-parts":[[2007,5]]},"published":{"date-parts":[[2007,3,29]]}}}